Mutations of the epidermal growth factor receptor gene in lung cancer: Biological and clinical implications

Cancer Research

Volumn 64, Issue 24, 2004, Pages 8919-8923

  Kosaka, Takayuki ^a,b   Yatabe, Yasushi ^a   Endoh, Hideki ^a,b   Kuwano, Hiroyuki ^b   Takahashi, Takashi ^a   Mitsudomi, Tetsuya ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b GUNMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN P53; PROTEIN TYROSINE KINASE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; EXON; FEMALE; FRAMESHIFT MUTATION; GENE DUPLICATION; GENE INSERTION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG CARCINOGENESIS; MALE; MULTIVARIATE ANALYSIS; NUCLEOTIDE SEQUENCE; ONCOGENE K RAS; PATHOLOGY; POINT MUTATION; PRIORITY JOURNAL;

ADENOCARCINOMA; ADULT; AGED; AMINO ACID SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; EXONS; FEMALE; GENE DELETION; GENES, ERBB-1; GENES, P53; GENES, RAS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION;

EID: 10844231985     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-2818     Document Type: Article

References (29)

1. Arteaga CL. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol 2002;29:3-9.
2. Bunn PA Jr, Franklin W. Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. Semin Oncol 2002;29:38-44.
3. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001;7:2958-70.
4. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-58.
5. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237-46.
6. Cappuzzo F, Gregore V, Rossi E, et al. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol 2003;21:2658-63.
7. Suzuki T, Nakagawa T, Endo H, et al. The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 ("Iressa") is not related to the expression of EGFR or HER-2 or to K-ras gene status. Lung Cancer 2003;42:35-41.
8. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (Wash D C) 2004;304:1497-500.
9. Lynch TJ. Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
10. Yatabe Y, Koga T, Mitsudomi T, Takahashi T. CK20 expression, CDX2 expression, K-ras mutation, and goblet cell morphology in a subset of lung adenocarcinomas. J Pathol 2004;203:645-52.
11. Yatabe Y, Mitsudomi T, Takahashi T. Maspin expression in normal lung and non-small-cell lung cancers: cellular property-associated expression under the control of promoter DNA methylation. Oncogene 2004;23:4041-9.
12. Travis WD, Colby TV, Sobin SH, Corrin B, Shimosato Y, Brambilia E. Histological typing of lung and pleural tumors, 3rd edition. New York: Springer-Verlag New York Inc.; 1999.
13. Denissenko MF, Pao A, Tang M, Pfeifer GP. Prefential formation of Benzo[a]pyrene adducts at lung cancer mutational hotspots in p53. Science (Wash D C) 1996;274:430-2.
14. Meuth M. The structure of mutation in mammalian cells. Biochim Biophys Acta 1990;1032:1-17.
15. Watanabe T, Hirono T, Koike T, et al. Registration of resected lung cancer in niigata prefecture. Jpn J Thorac Cardiovasc Surg 2004;52:225-30.
16. Minna JD, Gazdar AF, Sprang SR, Herz J. Cancer. A bull's eye for targeted lung cancer therapy. Science (Wash D C) 2004;304:1458-61.
17. Suzuki H, Takahashi T, Kuroishi T, Suyama M, Ariyoshi Y, Takahashi T. p53 mutations in non-small cell lung cancer in Japan: association between mutations and smoking. Cancer Res 1992;52:734-6.
18. Ahrendt SA, Decker PA, Alawi EA, et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer (Phila) 2001;92:1525-30.
19. Mitsudomi T, Oyama T, Nishida K, et al. Loss of heterozygosity at 3p in non-small cell lung cancer and its prognostic implication. Clin Cancer Res 1996;2:1185-9.
20. Cheng YW, Chiou HL, Sheu GT, et al. The association of human papillomavirus 16/18 infection with lung cancer among nonsmoking Taiwanese women. Cancer Res 2001;61:2799-803.
21. Ko YC, Cheng LS, Lee CH, et al. Chinese food cooking and lung cancer in women nonsmokers. Am J Epidemiol 2000;151:140-7.
22. Toyooka S, Pass HI, Shivapurkar N, et al. Aberrant methylation and simian virus 40 tag sequences in malignant mesothelioma. Cancer Res 2001;61:5727-30.
23. Minami Y, Tateno H. Associations between cigarette smoking and the risk of four leading cancers in Miyagi Prefecture, Japan: a multi-site case-control study. Cancer Sci 2003;94:540-7.
24. Kobrinsky NL, Klug MG, Hokanson PJ, Sjolander DE, Burd L. Impact of smoking on cancer stage at diagnosis. J Clin Oncol 2003;21:907-13.
25. Rodenhuis S, Slebos RJ. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res 1992;52:2665s-9s.
26. Otterson GA, Kratzke RA, Coxon A, Kim WK, Kaye FJ. Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wild type rb. Oncogene 1994;9:3375-8.
27. Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004;22:1103-9.
28. Yatabe Y. Role of expression of thyroid transcription factor-1 in pulmonary adenocarcinoma. In: Hyat MA, editor, Immunohistochemistry and in situ hybridization of human carcinomas. New York: Elsevier Science/Academic Press; 2004. p. 169-79.
29. Yatabe Y, Mitsudomi T, Takahashi T. TTF-1 expression in pulmonary adenocarcinomas. Am J Surg Pathol 2002;26:767-73.